# MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus

> **NCT03567824** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Pharmalyte Solutions LLC** · enrollment: 200 (estimated)

## Conditions studied

- Hypomagnesemia in Type 2 Diabetic Patients

## Interventions

- **DRUG:** Magnesium L-lactate dihydrate
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03567824
- **Lead sponsor:** Pharmalyte Solutions LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567824, "MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03567824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*